Form D · Pharmaceuticals
Chase Pharmaceuticals Corp
Washington, DC · CIK 0001509008
Offering snapshot reported Mar 28, 2016 · SEC filing
- Reported sold
- $12M Offering amount: $12M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 14, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 28, 2016 | Initial | $11,974,004 | No comparison | 14 | SEC filing |
| Feb 17, 2016 | Amendment | $3,500,000 | $500,000vs Aug 20, 2015 | 13 | SEC filing |
| Feb 17, 2016 | Initial | $0 | No comparison | 3 | SEC filing |
| Feb 16, 2016 | Initial | $0 | No comparison | 1 | SEC filing |
| Aug 20, 2015 | Initial | $3,000,000 | No comparison | 12 | SEC filing |
| May 30, 2014 | Initial | $6,137,999 | No comparison | 6 | SEC filing |
| Jan 5, 2011 | Initial | $1,200,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-260084
Source: Form D, filed Mar 28, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas N. Chase | Director, Executive |
| Kathleen Clarence Smith | Executive |
| Stephen Cunningham | Director |
| Richard P. Dulik | Executive |
| Douglas Ingram | Director, Executive |
| Karoly Nikolich | Director |
| Nayan Greg Parekh | Director |
| Greg N. Parekh | Director |
| N. Greg Parekh | Director |
| John M. Reher | Director |
| John M. Siebert | Executive |
| Vikram Sudarsan | Director |
| Raphael Wisniewski | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1825 K Street, Nw Suite 510
Washington, DC, 20006
Washington, DC, 20006